Get started
Author

Marta Ayala‐Ávila

Observed names: Avila, Marta Ayala, M. Ayala-Ávila, Marta Ayala Avila, Marta Ayala Ávila, Marta Ayala-Avila, Marta Ayala-Ávila
ORCID: 0000-0003-4441-4953
Observed ORCID: 0000-0003-4441-4953
OpenAlex ID: A5064618284
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)
2022 · Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, et al. · EClinicalMedicine · 68
PDF
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
2022 · Miladys Limonta-Fernández, Glay Chinea-Santiago, et al. · New Biotechnology · 61
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial
2014 · J.V. Gavilondo, F. Hernández-Bernal, et al. · Vaccine · 50
Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; a Cohort Study
2022 · Pedro I. Más-Bermejo, Félix O. Dickinson-Meneses, et al. · The Lancet Regional Health - Americas · 42
Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3
2019 · Olivia Cabanillas-Bernal, Salvador Dueñas, et al. · PLoS ONE · 36
PDF
CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors
2012 · Mónica Bequet-Romero, Yanelys Morera, et al. · Vaccine · 33
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study)
2023 · Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, et al. · The Lancet Regional Health - Americas · 25
Epidermal Growth Factor Intralesional Delivery in Chronic Wounds: The Pioneer and Standalone Technique for Reversing Wound Chronicity and Promoting Sustainable Healing
2024 · Jorge Berlanga-Acosta, Ariana Garcia-Ojalvo, et al. · International Journal of Molecular Sciences · 20
PDF
Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside
2018 · Yanelys Morera-Díaz, Jorge V. Gavilondo, et al. · Seminars in Oncology · 16
Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF
2016 · Javier Sánchez Ramírez, Yanelys Morera Díaz, et al. · Journal of Immunoassay and Immunochemistry · 10
Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate
2015 · Lincidio Pérez Sánchez, Yanelys Morera Díaz, et al. · Human Vaccines & Immunotherapeutics · 10
PDF
Endogenous Biological Drivers in Diabetic Lower Limb Wounds Recurrence: Hypothetical Reflections
2023 · Jorge Berlanga-Acosta, Ariana Garcia-Ojalvo, et al. · International Journal of Molecular Sciences · 9
PDF
Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models
2023 · Y. Morera-Díaz, C. Canaán-Haden, et al. · Cancer Letters · 7
Sequence determination of variable region genes of two human monoclonal antibodies against Neisseria meningitidis
1993 · Marta Ayala Avila, Javier Vazques, et al. · Gene · 7
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial
2024 · Gilda Lemos-Pérez, Yinet Barrese-Pérez, et al. · Vaccines · 6
PDF
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
2023 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · EClinicalMedicine · 6
PDF
HEBERSaVax immunotherapy combined with first‐line chemotherapy in advanced ovarian cancer: Phase II CENTAURO ‐4 trial results
2025 · Francisco Hernández‐Bernal, Katty‐Hind Selman‐Housein Bernal, et al. · International Journal of Cancer · 3
PDF
A synthetic humanized camelid single-domain antibody targeting VEGF exhibits in vitro antiangiogenic effects
2025 · Isabel Gonzalez-Moya, Yasmiana Muñoz, et al. · International Immunopharmacology · 2
Anti-VEGF immunotherapy with HEBERSaVax suppresses melanoma growth and metastasis via angiogenesis blockade and enhanced T-cell infiltration
2025 · Yanelys Morera-Díaz, Josune García-Sanmartín, et al. · Frontiers in Immunology · 1
PDF
Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys
2025 · Camila Canaán-Haden, Javier Sánchez-Ramírez, et al. · Vaccines · 1
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE)
2024 · Francisco Hernández-Bernal, Enrique Noa-Romero, et al. · Vaccine · 1
Correction to “Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study” [The Lancet Regional Health – Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366
2022 · Pedro I. Más-Bermejo, Félix O. Dickinson-Meneses, et al. · The Lancet Regional Health - Americas · 1
PDF
A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial for Adult Evaluation of the Efficacy and Safety of a Sars-Cov-2 Recombinant Spike Rbd Protein Vaccine (Abdala-3 Study)
2022 · Francisco Hernández-Bernal, Maria del Carmen Ricardo-Cobas, et al. · SSRN Electronic Journal · 1
Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study)
2022 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · SSRN Electronic Journal · 1
Perspectives on Cancer Immunotherapy Discussed at a 2025 Symposium in Cuba
2026 · Yuriy L. Orlov, Monica R. Bequet, et al. · Gene Expression
PDF
Works count: 36
Citation count: 417
H-index: 10
I10-index: 11
Year
Topic
Type